Rejuvenate Biomed has commenced a Phase 2 clinical trial evaluating RJx-01, a combination therapy of metformin and galantamine, aimed at addressing sarcopenia in older adults. The study will involve 130 participants aged 65 and above, who have experienced hospitalization due to chronic obstructive pulmonary disease (COPD). The trial will assess the therapy’s impact on muscle strength, function, and overall quality of life.
Sarcopenia, characterized by the progressive loss of muscle mass and strength, is prevalent among the elderly and often exacerbated by conditions like COPD. Rejuvenate Biomed’s approach combines metformin, a widely used diabetes medication known for its potential anti-aging effects, with galantamine, a cholinesterase inhibitor traditionally used in Alzheimer’s disease treatment, to target multiple pathways involved in muscle degradation.
The company aims to determine whether this combination can mitigate the adverse effects of muscle loss, thereby improving patient outcomes and reducing healthcare burdens associated with frailty and disability in the aging population.
As featured in Longevity.Technology, the trial’s outcomes could pave the way for novel therapeutic strategies in combating sarcopenia and enhancing the quality of life for older adults.
